1079 related articles for article (PubMed ID: 17603880)
1. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
[TBL] [Abstract][Full Text] [Related]
2. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
3. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy.
Bechini A; Levi M; Boccalini S; Tiscione E; Balocchini E; Canessa C; Azzari C; Bonanni P
Vaccine; 2012 Oct; 30(45):6396-401. PubMed ID: 22921931
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
[TBL] [Abstract][Full Text] [Related]
5. Optimizing protection against meningococcal disease.
Reisinger KS; Black S; Stoddard JJ
Clin Pediatr (Phila); 2010 Jun; 49(6):586-97. PubMed ID: 20089551
[TBL] [Abstract][Full Text] [Related]
6. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States.
Lingappa JR; Rosenstein N; Zell ER; Shutt KA; Schuchat A; Perkins BA;
Vaccine; 2001 Aug; 19(31):4566-75. PubMed ID: 11483285
[TBL] [Abstract][Full Text] [Related]
7. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.
Trotter CL; Gay NJ; Edmunds WJ
Am J Epidemiol; 2005 Jul; 162(1):89-100. PubMed ID: 15961591
[TBL] [Abstract][Full Text] [Related]
8. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
[TBL] [Abstract][Full Text] [Related]
9. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE;
MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099
[TBL] [Abstract][Full Text] [Related]
10. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
[TBL] [Abstract][Full Text] [Related]
11. Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults.
Pace D
Future Microbiol; 2010 Nov; 5(11):1629-40. PubMed ID: 21133685
[TBL] [Abstract][Full Text] [Related]
12. Indirect effects by meningococcal vaccines: herd protection versus herd immunity.
Bröker M
Hum Vaccin; 2011 Aug; 7(8):881-2. PubMed ID: 21785283
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States.
Mbaeyi S; Pondo T; Blain A; Yankey D; Potts C; Cohn A; Hariri S; Shang N; MacNeil JR
JAMA Pediatr; 2020 Sep; 174(9):843-851. PubMed ID: 32687590
[TBL] [Abstract][Full Text] [Related]
14. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP
Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585
[TBL] [Abstract][Full Text] [Related]
15. Evolving meningococcal immunization strategies.
Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
[TBL] [Abstract][Full Text] [Related]
16. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
[TBL] [Abstract][Full Text] [Related]
19. Invasive bacterial diseases: national surveillance in Italy and vaccination coverage in the Local Health Agency 4 "Chiavarese", Liguria region (Italy).
Trucchi C; Zoppi G
J Prev Med Hyg; 2012 Jun; 53(2):120-4. PubMed ID: 23240174
[TBL] [Abstract][Full Text] [Related]
20. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study.
Campbell H; Andrews N; Parikh SR; White J; Edelstein M; Bai X; Lucidarme J; Borrow R; Ramsay ME; Ladhani SN
Lancet Child Adolesc Health; 2022 Feb; 6(2):96-105. PubMed ID: 34883094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
